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ABSTRACT The use of recombinant attenuated Salmonella vaccine (RASV) strains is
a promising strategy for presenting heterologous antigens to the mammalian im-
mune system to induce both cellular and humoral immune responses. However,
studies on RASV development differ on where heterologous antigens are expressed
and localized within the bacterium, and it is unclear how antigen localization modu-
lates the immune response. Previously, we exploited the plasmid-encoded toxin
(Pet) autotransporter system for accumulation of heterologous antigens in cell cul-
ture supernatant. In the present study, this Pet system was used to express early se-
cretory antigen 6 (ESAT-6), an immunodominant and diagnostic antigen from Myco-
bacterium tuberculosis, in Salmonella enterica serovar Typhimurium strain SL3261.
Three strains were generated, whereby ESAT-6 was expressed as a cytoplasmic
(SL3261/cyto), surface-bound (SL3261/surf), or secreted (SL3261/sec) antigen. Using
these RASVs, the relationship between antigen localization and immunogenicity in
infected C57BL/6 mice was systematically examined. Using puriﬁed antigen and spe-
ciﬁc tetramers, we showed that mice infected with the SL3261/surf or SL3261/sec
strain generated large numbers of Th1 CD4 ESAT-6 splenic T cells compared to
those of mice infected with SL3261/cyto. While all mice showed ESAT-6-speciﬁc anti-
body responses when infected with SL3261/surf or SL3261/sec, peak total serum IgG
antibody titers were reached more rapidly in mice that received SL3261/sec. Thus,
how antigen is localized after production within bacteria has a more marked effect
on the antibody response than on the CD4 T cell response, which might inﬂuence
the chosen strategy to localize recombinant antigen in RASVs.
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Vaccines based on attenuated bacterial strains can generate protective immunityagainst disease caused by the parent strain (1–3). Attenuated strains of Salmonella
spp. can be modiﬁed to express heterologous antigens from a range of viral, bacterial,
protozoan, and fungal agents and, as such, have been named recombinant attenuated
Salmonella vaccine (RASV) strains (4–10). The capacity of RASVs to elicit protective
immune responses is heavily dependent upon the subcellular localization of antigen
expression. For example, many systems have been developed to overexpress heterol-
ogous antigens within the cytoplasm (11). However, these systems often show poor
immunogenicity in mice, and their application in vaccine development has been
questioned (12). In light of this, different bacterial secretion systems (e.g., types 1, 3, and
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5) have been exploited to target recombinant antigens to the bacterial cell surface or
extracellular milieu (13–20).
The type 5 autotransporter (AT) secretion system represents the most simplistic
molecular machinery for protein secretion in Gram-negative bacteria (21–26). Multiple
AT platforms have been exploited to present antigens on the bacterial cell surface,
including fusions with Ag43, AIDA-I, and Hbp from Escherichia spp. and MisL from
Salmonella spp., and this approach has been termed autodisplay (27–30). Many studies
have reported antigen-speciﬁc cellular and humoral responses to heterologous anti-
gens presented via autodisplay and, in some cases, protection against challenge
infection (17, 30–32). Although autodisplay has become a system of choice for recom-
binant protein expression for various applications, there are limited studies comparing
the effects of secreted versus cell surface-bound antigen on host immune responses
(33). Nevertheless, some studies have suggested that protrusion of the target antigen
away from bacterial cell surface structures may facilitate protective immunity (34). This
implies that the mode of antigen presentation to the immune system, rather than
intrinsic properties of the antigen and/or expression levels, can determine immunoge-
nicity. Thus, there is a need to understand how the cellular localization of an antigen
inﬂuences the immune response induced by RASVs.
In this study, we utilized the type 5 autotransporter plasmid-encoded toxin (Pet)
(18), which can be modiﬁed to support the accumulation of secreted or surface-bound
recombinant antigen. Thus, this platform presents a unique opportunity to directly
compare the inﬂuences of differentially localized antigens on host immune responses.
Using Salmonella enterica serovar Typhimurium strain SL3261, we exploited Pet to
deliver cytoplasmic, secreted, and surface-bound forms of a model antigen to the
immune system. Early secretory antigen 6 (ESAT-6) of Mycobacterium tuberculosis was
chosen as the model antigen because it is a nonnative protein which induces speciﬁc
cells that can be detected ex vivo. S. Typhimurium SL3261 was chosen for delivery
because it is an attenuated strain that is able to cause a sustained yet limited infection
of mice and disseminates to multiple organs, such as the spleen and liver (35). Mice
infected with such attenuated strains of Salmonella spp. resolve the infection over a
period of 5 to 6 weeks through the induction of CD4 Th1 cells and IgG antibody (35).
The deﬁned kinetics of this Salmonella infection allows antigen-speciﬁc T cell and
antibody responses to be monitored. Our studies show that cell surface-bound or
secreted antigen drives a signiﬁcantly larger proportion of ESAT-6-speciﬁc T cells than
that seen with cytoplasmic antigen. Furthermore, we show that the total ESAT-6-
speciﬁc serum IgG antibody levels at 21 days postinfection are signiﬁcantly higher
when ESAT-6 is presented as a secreted antigen. Our data present a detailed compar-
ison of AT-mediated secretion versus surface presentation of a recombinant antigen in
RASV-infected mice and provide novel insights into the nature of cellular and humoral
immune responses against antigens localized to different subcellular compartments
within the RASV strain.
RESULTS
Construction and characterization of RASVs expressing ESAT-6-Pet chimeric
proteins. Previously, we showed that the Pet autotransporter can be exploited to
secrete a range of heterologous proteins into the culture medium in a natively folded
and functional state (18). Moreover, a cleavage-deﬁcient Pet variant, Pet*, can be used
to assemble heterologous proteins on the bacterial cell surface. Here we generated
three ESAT-6-Pet chimeric constructs, pettac-ESAT6-Pet, pettac-ESAT6-Pet*, and pettac-
ESAT6-cyto, expressing secreted, surface-bound, and cytoplasmic ESAT-6-Pet proteins,
respectively (Fig. 1A and Table 1). These fusions were cloned into the pettac vector, a
modiﬁed pET22b plasmid with the T7 promoter exchanged for a tac promoter,
allowing constitutive gene expression (36). This vector was tested previously for its
stability and validity in antigen expression for immunization studies with Salmonella
species (36, 37). The recombinant plasmids, including a vector-only control, were
transformed into a well-characterized RASV strain (Salmonella enterica serovar Typhi-
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murium SL3261 aroA) (10). From here on, the SL3261 strains expressing ESAT-6 in
surface-bound, secreted, and cytoplasmic forms are referred to as SL3261/surf, SL3261/
sec, and SL3261/cyto, respectively. All ESAT-6-expressing RASV strains were tested for
ESAT-6-Pet expression. Whole-cell lysates and outer membrane and secreted protein
FIG 1 Construction and characterization of recombinant attenuated Salmonella vaccine (RASV) strains. (A) Schematic of Pet AT and the secreted, surface-bound,
and cytoplasmic derivatives containing ESAT-6, cloned within the indicated BglII and BstBI restriction sites. The following Pet domains are shown: signal
sequence (SS), passenger domain, -helix (), and -barrel. The numbers above Pet denote amino acid positions. Amino acid position 1018 indicates where
intrabarrel cleavage occurs to mediate secretion. The red crosses denote amino acid substitutions within the -helix and -barrel which enable surface
localization of the Pet chimera (18). (B) SDS-PAGE (top) and Western blot (bottom) analyses of ESAT-6-Pet protein localization in cell lysate, envelope, and
supernatant fractions prepared from the indicated RASV strains expressing vector only (SL3261/vec) or the cytoplasmic (SL3261/cyto), surface-bound
(SL3261/surf), or secreted (SL3261/sec) ESAT-6-Pet fusion. The expressed protein fusions are indicated by arrows in the SDS-PAGE gel and were also detected
by Western immunoblotting with anti-ESAT-6. Lane M, protein markers (kilodaltons). Note the additional 30-kDa band (marked with asterisk) appearing in the
cell envelope fraction of SL3261/sec, which corresponds to the Pet -barrel localized in the outer membrane. (C and D) Conﬁrmation of subcellular localization
of ESAT-6-Pet fusions in the indicated RASV strains by immunoﬂuorescence (C) and ﬂow cytometry (D) analyses. Protein fusions were detected using antibodies
speciﬁc to ESAT-6 in conjunction with ﬂuorescein isothiocyanate (FITC)-conjugated secondary antibodies. Nonpermeabilized cells were used for ﬂow cytometry,
while permeabilized cells were also used in the immunoﬂuorescence analysis to allow intracellular labeling of the cytoplasmic ESAT-6-Pet fusion. (E) Growth
kinetics of the untransformed SL3261 strain and the indicated RASV strains. Overnight cultures were subcultured into fresh LB broth and normalized to an OD600
of 0.05 before measurements were taken every hour for 7 h. Individual data points represent means  SEM for three biological replicates.
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fractions were prepared from bacterial cultures harvested at the logarithmic phase of
growth. Figure 1 demonstrates that ESAT-6-Pet was localized to the expected subcel-
lular compartments as examined by Western immunoblotting (Fig. 1B), indirect immu-
noﬂuorescence assay (Fig. 1C), and ﬂow cytometry analysis (Fig. 1D). Furthermore, using
whole-cell lysates, cell envelope and supernatant fractions, and densitometric analysis
of Western blots, we conﬁrmed that ESAT-6 levels in the cytoplasmic, supernatant, and
membrane fractions were comparable between the strains at the exponential phase of
growth, with only the SL3261/sec strain displaying a slight increase of ESAT-6 produc-
tion (see Fig. S1 in the supplemental material). All strains grew with similar kinetics
during the logarithmic phase, although SL3261/cyto had a slightly extended lag phase
(Fig. 1E). Thus, we generated RASV strains that are able to localize ESAT-6-Pet expres-
sion to different cellular compartments and that show comparable growth rates and
antigen expression levels.
RASV strains expressing surface-bound and secreted ESAT-6 elicit signiﬁcant
ESAT-6-speciﬁc T cell responses.We next sought to investigate the endogenous T cell
response to differentially presented antigen. To do this, we analyzed the number of
ESAT-6-speciﬁc CD4 T cells and their capacity to produce the classical Th1-associated
cytokine, gamma interferon (IFN-), using mouse-speciﬁc tetramers and intracellular
cytokine staining. Wild-type mice were infected intraperitoneally (i.p.) with 105 CFU of
SL3261/surf, SL3261/sec, SL3261/cyto, or wild-type SL3261. At 7 days postinfection,
mice were injected intravenously (i.v.) with an ESAT-6 peptide to restimulate ESAT-6-
speciﬁc T cells. Four hours later, splenocytes were harvested, and CD4 T cells were
stained for speciﬁcity for ESAT-6 and IFN- expression (a representative gating strategy
is shown in Fig. 2A). The number of CD4 ESAT-6 speciﬁc T cells in the spleen
increased for mice infected with SL3261/surf or SL3261/sec compared to that for mice
infected with SL3261/cyto or the SL3261 control strain. Furthermore, after infection
with SL3261/surf or SL3261/sec, 10 to 30% of ESAT-6-speciﬁc T cells produced IFN-,
indicating differentiation to a Th1 phenotype. The proportion of T cells producing IFN-
tended to be higher in the SL3261/surf-infected mice than in the SL3261/sec-infected
mice (Fig. 2C), although the difference was not signiﬁcant. The failure to observe
ESAT-6 T cells after immunization with SL3261/cyto was not due to defects in bacterial
colonization between the ESAT-6 strains, as bacteria persisted in similar numbers for all
ESAT-6-producing strains (Fig. 2D and E). Importantly, there were no signiﬁcant differ-
ences in plasmid stability in bacteria recovered from mouse spleens and livers postim-
munization, as assessed by colony replica plating on nutrient agar with and without
carbenicillin. All constructs showed between 80 and 100% plasmid retention (Table
S1). These results indicate that SL3261/surf and SL3261/sec, but not SL3261/cyto, are
capable of inducing an endogenous, antigen-speciﬁc CD4 T cell response.
TABLE 1 Bacterial strains and plasmids used in this study
Bacterial strain or
plasmid Description
Source or
reference
Strains
E. coli NEB 5-alpha fhuA2 Δ(argF-lacZ)U169 phoA glnV44 80 Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17 NEB
E. coli BL21*(DE3) F ompT gal dcm lon hsdSB(rB mB) rne131 (DE3 [lacI lacUV5-T7 gene 1 ind-1 sam-7 nin-5]) Novagen
Salmonella enterica
Typhimurium SL3261
Salmonella enterica serovar Typhimurium SL1344 derivative containing an aroA deletion 10
Plasmids
pASK-ESAT6-Pet-BB pASK-Pet with esxA (ESAT-6) insertion between BglII and BstBI sites of wild-type pet gene 18
pASK-ESAT6-Pet* pASK-Pet with esxA (ESAT-6) insertion between BglII and BstBI sites of cleavage-deﬁcient pet gene 18
pASK-His6-Pet pASK vector expressing His6-tagged Pet 18
pettacOVA Modiﬁed pET22b with ovalbumin gene cloned between NdeI and XhoI sites; Ampr 36
pettac pettacOVA derivative generated by OVA excision and vector religation This study
pettac-ESAT6-Pet pettac expressing secreted ESAT-6-Pet This study
pettac-ESAT6-Pet* pettac expressing surface-bound ESAT-6-Pet This study
pettac-ESAT6-Pet-cyto pettac expressing cytoplasmic ESAT-6-Pet This study
pASK-His6-ESAT6-Pet-BP pASK-His6-Pet derivative containing esxA (ESAT-6) insertion between BglII and PstI sites of pet This study
pET-His6-ESAT6-Pet-BP pET22b expressing His6-ESAT6-Pet fusion This study
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Secreted and surface-bound ESAT-6 antigens drive a speciﬁc and sustained T
cell response in infected mice. Having shown the induction of ESAT-6-speciﬁc T cell
responses in early infection, we next sought to investigate whether these T cell
responses to secreted and surface-bound ESAT-6 were sustained over the course of
infection. To do this, mice were infected with the indicated SL3261 strains, and at 42
days postinfection, the cytokine-producing (IL-2 IFN-) T cell response was examined
(the gating strategy is shown in Fig. 3A). Immunization with ESAT-6-expressing RASVs
produced a signiﬁcant proportion of CD4 IL-2 IFN- T cells. These T cells were
readily detectable in the spleens of both groups that were immunized with ESAT-6-
expressing strains, although nearly twice as many were detected in spleens of mice that
received SL3261/surf (Fig. 3B). This difference was not due to a difference between the
levels of ESAT-6 expressed by the immunized strains, as levels of ESAT-6 production
were similar for all strains recovered from infected mice at day 42 (data not shown).
Moreover, there was no correlation between numbers of responsive splenic T cells and
numbers of bacteria per spleen (data not shown). Thus, both SL3261/surf and SL3261/
sec can induce long-term CD4 Th1 cell responses.
Secreted antigen changes the dynamics of the ESAT-6-speciﬁc antibody re-
sponse during the course of Salmonella infection. Given that endogenous T cells did
FIG 2 SL3261/sec and SL3261/surf elicit ESAT-6-speciﬁc T cell responses in immunized mice. C57BL/6 mice were infected with untransformed Salmonella SL3261
and the SL3261/sec, SL3261/surf, and SL3261/cyto RASV strains, expressing secreted, surface, and cytoplasmic ESAT-6, respectively. At 7 days postinfection, mice
were injected i.v. with an ESAT-6 peptide for in vivo restimulation of ESAT-6-speciﬁc T cell populations. Splenic ESAT-6 CD4 T cells were detected by staining
with an ESAT-6 MHC II tetramer and anti-IFN- to assess cytokine production. (A) Representative ﬂow cytometry plots of splenic lymphocyte populations from
an RASV-immunized mouse, showing the gating sequence to identify ESAT-6 IFN- CD4 T cells. The labels below the ﬂow cytometry plots indicate the
phenotypes of the cells present within the gated regions. (B) Numbers of ESAT-6-speciﬁc CD4 T cells in spleens of mice immunized with the indicated RASV
strains, detected using an ESAT-6 MHC II tetramer. (C) Proportions of cells producing IFN- in the responding ESAT-6 CD4 T cell populations shown in panel
B. (D and E) Numbers of CFU recovered from mouse spleens (D) and livers (E) at 7 days postinfection. Data from two experiments are shown, with a combined
cohort size of 4 to 6 mice. P values were calculated using the Mann-Whitney t test (*, P  0.05; **, P  0.01; ***, P  0.001). A median bar is shown for each
group.
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not respond to cytoplasmic ESAT-6 (SL3261/cyto), this variant was excluded from
subsequent analyses. To investigate the antibody responses induced by the two
ESAT-6-expressing strains, mice were infected i.p. for periods of up to 42 days, and
blood samples were taken at days 21, 35, and 42 to measure ESAT-6 and lipopolysac-
charide (LPS) IgG antibody titers. Marked antibody responses to the immunodominant
Salmonella antigen LPS were detected at all time points examined for mice infected
with ESAT-6-expressing strains (representative data for day 42 are shown in Fig. 4A).
ESAT-6-speciﬁc total IgG antibody titers were 100-fold higher in mice infected with
SL3261/sec than in those infected with SL3261/surf at 21 days postinfection, while
similar IgG levels were detected between these strains at later time points (Fig. 4B).
Assessment of IgG isotypes at day 42 postinfection showed that IgG2a and IgG2b, but
not IgG1, were detected, with no difference in isotype pattern observed between
SL3261/sec- and SL3261/surf-infected mice. These results indicate that mice were
equally responsive to Salmonella infection, yet SL3261/sec induced peak anti-ESAT-6
IgG antibody titers more rapidly than SL3261/surf did.
DISCUSSION
Multiple studies have detailed the use of RASVs to generate protective immunity
against heterologous pathogens; however, the effect of antigen localization within
RASVs remains unclear (4, 5, 7). Here we provide a systematic comparison of T and B cell
responses to differentially presented ESAT-6, which can likely inform the design of
RASVs in vaccine development. Multiple studies have described immunogenicity
against target antigens presented for surface localization by autodisplay in Salmonella
spp. (17, 31, 32). However, this is the ﬁrst time that the AT system has been used to
investigate immune responses to ESAT-6 in vivo by using tetramers to detect antigen-
speciﬁc T cells in the context of RASV development. T cell responses to ESAT-6 are used
clinically to identify latent tuberculosis infections, and this antigen contains multiple
epitopes that are recognized by humans and mice. Additionally, Mollenkopf et al.
developed a RASV that secreted ESAT-6 and showed that vaccination of mice with a
single dose of Salmonella could lead to a reduction in the numbers of tubercle bacilli
in the lungs after subsequent challenge with M. tuberculosis (38). Thus, this makes
understanding the relationship between immune responses and antigen localization
particularly relevant for translation to humans.
The differences observed in the T cell responses to this antigen are not likely to
reﬂect differences in colonization by the different RASV strains used, as the strains grew
well in vitro, readily expressed ESAT-6, were recoverable at similar levels in vivo, and
retained their respective plasmids. Furthermore, the inﬂuence of the site of antigen
FIG 3 Characterization of T cell immune responses to ESAT-6-expressing RASV strains at 42 days postinfection. C57BL/6 mice were infected with Salmonella
SL3261 strains expressing secreted or surface-bound ESAT-6 or with the untransformed SL3261 control. At 42 days postimmunization, ESAT-6-speciﬁc T cells
were restimulated with an ESAT-6 peptide. Functional CD4 T cells were identiﬁed by staining for the intracellular cytokines IFN- and IL-2. (A) Representative
ﬂow cytometry plots of stained splenocytes from an RASV-immunized mouse, showing the gating sequence to identify IFN- IL-2 CD4 T cells. (B) Numbers
of IFN- IL-2 CD4 T cells in spleens of mice infected with ESAT-6-expressing RASV strains or a negative control (SL3261). Mouse cohorts included 5 or 6
animals. The data shown are representative of two independent experiments. P values were calculated using the Mann-Whitney t test (*, P  0.05; **, P  0.01;
***, P  0.001). A median bar is shown for each group.
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expression is emphasized by the ﬁnding that SL3261/cyto showed similar levels of
antigen production yet induced minimal T cell responses. Thus, any differences ob-
served in the immunogenicity of ESAT-6 were more likely to be due to antigen
localization than to differences in colonization.
In mice receiving SL3261/cyto, we were unable to detect ESAT-6-speciﬁc T cell
responses. The differences in these results may lie in the accessibility of antigen to
antigen-presenting cells. If so, then this suggests that there may be too few peptides
derived from cytoplasm-restricted antigens presented via major histocompatibility
complex class II (MHC II) to compete for rare endogenous T cell responses. Indeed, it
may be signiﬁcant that, for Salmonella spp., the majority of T cell epitopes identiﬁed
originate from surface or secreted proteins (39, 40). Nevertheless, T cell responses to
cytoplasmically localized ESAT-6 have been described previously (41). The reasons for
the discrepancy between the study of Hall and colleagues (41) and the current study
are unclear and may relate to the different approaches used to identify antigen-speciﬁc
T cell responses.
In contrast to the absence of T cell responses to SL3261/cyto, all mice infected with
SL3261/surf and SL3261/sec generated signiﬁcant numbers of ESAT-6-speciﬁc T cells
compared to those with SL3261 alone. Many of the ESAT-6-speciﬁc T cells had a Th1
phenotype, reﬂecting the Th1 response known to be induced in response to S.
Typhimurium in the spleen at the examined time points (42, 43). Immunization with
FIG 4 ESAT-6-speciﬁc antibody responses in RASV-immunized mice. (A and B) Salmonella LPS-speciﬁc (A) and ESAT-6-
speciﬁc (B) IgG titers in mouse blood samples taken 21 (D21), 35 (D35), and 42 (D42) days after infection with the indicated
RASV strains. (C) Analysis of ESAT-6-speciﬁc IgG isotypes in blood samples taken at 42 days postimmunization. Antibody
titers were determined using the speciﬁed threshold OD method. A median bar is shown for each group. The data are
representative of two independent experiments. Each mouse cohort included 5 or 6 mice. P values were calculated using
the Mann-Whitney t test (*, P 0.05; **, P 0.01; ***, P 0.001; ns, not signiﬁcant). A median bar is shown for each group.
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SL3261/surf tended to result in a greater speciﬁc Th1 response than that seen after
immunization with SL3261/sec, a trend that was consistent at both 7 (Fig. 2C) and 42
(Fig. 3B) days postinfection. It is unclear why SL3261/sec should lead to a smaller
number of Th1 cells, but this may be due to a stronger adjuvant effect of T cell receptor
(TCR) ligands on the cell surface leading to their co-uptake by the same antigen-
presenting cell. It is also important that our previous studies examining the endoge-
nous Th1 response to Salmonella infection revealed that all IFN- CD4 T cells
expressed T-bet, a transcription factor important for the control of Salmonella, yet not
all T-bet-expressing CD4 T cells were IFN- (44). Thus, these RASV strains may drive
the expansion of additional T cell subsets, and further work is needed to investigate
these in terms of their cytokine and transcription factor signature and whether the
balance between different T cell subsets for this antigen is stable. In previous work,
McSorley and colleagues showed that the Th cell response to an individual antigen
could differ depending upon when after infection the response was assessed (40).
Moreover, ESAT-6 can inhibit IFN- production by T cells in response to M. tuberculosis,
despite Th1 responses to ESAT-6 being detected in humans and mice in vivo (45, 46).
Therefore, in our model, it is possible that secretion from Salmonella enables ESAT-6 to
suppress IFN- production, while ESAT-6 immobilized on the cell surface is unable to
impart this function. Such a modulation of Th1 responses to S. Typhimurium has been
observed in mice coimmunized with S. Typhimurium and soluble FliC (44). Furthermore,
since individual antigens expressed by S. Typhimurium can contain multiple epitopes
(47), presentation of ESAT-6 as a secreted, soluble antigen rather than restricted on the
bacterial cell surface may alter the availability of epitopes presented by antigen-
presenting cells, thereby inﬂuencing the induction and phenotype of responsive T cells.
Mice immunized with SL3261/sec generated a signiﬁcantly higher and sustained
antibody response than that of mice immunized with SL3261/surf. At 21 days postin-
fection, total ESAT-6-speciﬁc IgG levels were nearly 100-fold higher in the SL3261/sec-
immunized mice than in SL3261/surf-immunized mice, yet from day 35 the antibody
levels in both groups were comparable. This suggests that secretion of antigen by the
RASV provides an early advantage in driving speciﬁc antibody responses. This may be
useful if an early antibody response is necessary. The reasons for the discordant
induction of early antibody responses to ESAT-6 seen after immunization with the
different vectors may reﬂect the diverse B cell epitopes exposed on the secreted
protein compared to those on surface-localized ESAT-6. Furthermore, structures that
protrude from the cell surface, such as the LPS O chain, can restrict the access of
immunoglobulin to the bacterial outer membrane (48, 49). Hence, when ESAT-6 is
expressed on the bacterial cell surface, certain epitopes may be shielded by cell surface
structures, while secreted ESAT-6 may be more accessible to B cells and antibody,
thereby triggering a more rapid antibody response. Otherwise, the difference in IgG
titers between surface and secreted antigens at day 21 may reﬂect the atypical
antibody response to Salmonella induced in mice, which differs substantially from that
observed to most soluble antigens (50). Thus, delivery of secreted antigen by an RASV
strain can induce responses with kinetics that resemble those observed after immuni-
zation with a puriﬁed antigen in subunit vaccines yet offers the advantage of antigen
delivery without the need for costly and time-consuming protein puriﬁcation.
There are limitations to this study. It is not clear how the levels of antigen produced
in vitro reﬂect those in vivo or if there were effects of ESAT-6 production on the biology
of the host strain. Furthermore, although both surface-expressing and secreting strains
induced robust immune responses, we do not know if the half-life of ESAT-6 differed
depending upon if it was surface localized or secreted. Moreover, further mechanistic
studies are required to determine why secreted antigen drives a rapid antibody
response yet leads to a less pronounced Th1 response than that with surface-localized
antigen. Also, given that induction of both T and B cell responses to RASVs is desirable
for their maximum efﬁcacy (12), it would be of great interest to develop a functional
assessment of the response, for instance, to determine whether our observed ESAT-6-
speciﬁc T and B cell immune responses toward cell surface or secreted ESAT-6 confer
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protection against challenge with M. tuberculosis. In summary, this report provides a
detailed analysis of immune responses toward differentially presented antigen and
shows that altering the site of antigen localization provides a ﬂexible platform for
modulating the magnitude and timing of T and B cell responses to the target antigen.
This is attractive for the design of RASVs but is also of interest to further our under-
standing of how antigen-speciﬁc responses to bacterially expressed antigens develop.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Escherichia coli NEB 5-alpha (high-efﬁciency competent
cells; NEB) and TOP10 (Invitrogen) were used for cloning. E. coli TOP10 and BL21*(DE3) (Novagen) were
used in secretion experiments and for large-scale protein expression. Salmonella enterica Typhimurium
SL3261 (51) was used in mouse immunization studies. Bacteria were grown at 37°C in Luria-Bertani broth
(LB) or on LB agar (1.5% [wt/vol]) plates supplemented with 100 g/ml carbenicillin, as appropriate.
Preparation of electrocompetent Salmonella cells and electroporation. An overnight culture of
S. Typhimurium SL3261 was inoculated into fresh LB medium and grown at 37°C with aeration to an
optical density at 600 nm (OD600) of 0.8. The culture was incubated in a 42°C shaker for 15 min,
followed by 10 min of incubation on ice (with shaking). The cells were harvested by centrifugation,
washed twice in ice-cold MOPS buffer (20% glycerol, 1 mMMOPS [morpholinepropanesulfonic acid]), and
resuspended in MOPS buffer. Cells were then either used immediately or snap-frozen and stored at
80°C for later use. For electroporation, cells were mixed with plasmid DNA and transferred immediately
into a cold 0.2-cm cuvette. The cells were pulsed at 2.5 kV in an electroporator and immediately
supplemented with warm SOC (New England Biolabs) medium. The cells were recovered for 1.5 h at 37°C
with aeration and plated onto appropriate selection agar plates.
Growth curves. Overnight cultures were diluted in fresh LB broth (with carbenicillin where appro-
priate) to an OD600 of 0.05 and incubated at 37°C for 7 h with aeration. The culture OD600 was recorded
hourly for 7 h. Three replicates of each culture were used to generate growth curves.
Conﬁrmation of protein secretion in E. coli and S. Typhimurium. Overnight bacterial cultures
were diluted in fresh LB medium containing carbenicillin and grown at 37°C with aeration. Cultures
containing pettac vector derivatives were grown without induction, and culture supernatants were
collected at 5 h postinoculation. Cultures containing derivatives of pASK or pET vectors were grown to
an OD600 of 0.5, followed by induction of protein expression with anhydrotetracycline (200 g/liter) or
IPTG (isopropyl--D-thiogalactopyranoside) (0.5 mM), respectively. The supernatants for secreted protein
analysis were collected at 1.5 to 2 h postinduction. Secreted protein and cell envelope fractions were
prepared as described previously (18) and analyzed by SDS-PAGE and Western immunoblotting along-
side the whole-cell lysates.
Molecular biology techniques, SDS-PAGE, Western immunoblotting, indirect ﬂow cytometry,
and immunoﬂuorescence microscopy. All techniques were performed as described previously (18).
Brieﬂy, proteins were separated in NuPAGE 4 to 12% bis-Tris/MES gels (Life Technologies). Protein
transfer to nitrocellulose membranes was done using an iBlot dry blot system (Life Technologies) per the
manufacturer’s instructions. For ESAT-6 detection by Western immunoblotting, primary monoclonal
anti-ESAT-6 (Abcam) (1/2,000 dilution) and secondary alkaline phosphatase (AP)-conjugated anti-mouse
(Sigma) antibodies were used. Measurement of band intensities was done using Quantity One software
(with a rolling disk of 100 for lane background subtraction applied). The peak density obtained for each
detected ESAT-6 band was multiplied by a dilution factor to generate the relative level of ESAT-6. For
immunoﬂuorescence microscopy and ﬂow cytometry, polyclonal rabbit anti-ESAT-6 (1/300 dilution) and
Alexa Fluor 488-conjugated goat anti-rabbit (1/500 dilution) (Invitrogen) antibodies were used as primary
and secondary antibodies, respectively. When necessary, the cells were ﬁxed and permeabilized. For this
purpose, cell pellets were incubated in 4% paraformaldehyde–phosphate-buffered saline (PBS) for 20
min on ice and washed thoroughly with PBS. The ﬁxed cells were permeabilized in PBS-0.1% Triton X for
45 min at room temperature, washed twice with PBS, incubated with 100 g/ml lysozyme and 5 mM
EDTA for 45 min at room temperature, and again washed with PBS before labeling.
Plasmid construction. To generate ESAT-6-Pet expression cassettes in the pettac vector, an esxA-pet
chimeric DNA was PCR ampliﬁed from pASK-ESAT6-Pet-BB and pASK-ESAT6-Pet* (Table 1) with the
NdeI-Pet-F and XhoI-Pet-R primers, respectively (Table 2). The PCR fragments obtained were digested
with NdeI and XhoI and ligated into the pettac backbone, excised from pettacOVA with the same
TABLE 2 Primers used in this study
Primer Sequence (5=-3=)a
NdeI-pet-F TTAACATATGAACAAAATCTACTCTATCAAATAC
XhoI-pet-R AACGCTCGAGTTATCAGAAAGAGTAACGGAAG
HindIII-pet-R CGAAGCTTTTATCAATGATGATGATG
NdeI-(noSS)-ESAT6-F TTATCATATGTCTCTGAAAATCTCTCAGGCGG
BglII-ESAT6-F GCGAGATCTGATGACCGAACAGCAGTGGAAC
PstI-ESAT6-R ATCCTGCAGAGCCGCCAGCGAACATGC
pET22b_F_seq GTGATGTCGGCGATATAGGC
aRestriction sites are shown in bold.
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restriction enzymes, generating pettac-ESAT6-Pet (SL3261/sec) and pettac-ESAT6-Pet* (SL3261/surf),
respectively. To construct pettac-ESAT6-Pet-cyto, an esxA-pet fragment lacking the pet signal sequence
was PCR ampliﬁed from pASK-ESAT6-Pet-BB by use of the NdeI-(noSS)-ESAT6-F and XhoI-Pet-R primers
(Table 2), followed by ligation into NdeI- and XhoI-digested pettacOVA. To construct pASK-His6-ESAT6-
Pet-BP, the fragment encoding ESAT-6 was PCR ampliﬁed from pASK-ESAT6-Pet-BB with primers BglII-
ESAT6-F and PstI-ESAT6-R and cloned into BglII- and PstI-digested pASK-His6-Pet. pET-His6-ESAT6-Pet-BP
was created by subcloning of the SacI-SalI His6-ESAT6-Pet fragment from pASK-His6-ESAT6-Pet-BP into
pET-Pet digested with SacI and SalI. All ﬁnal constructs were checked by appropriate restriction digestion
and/or sequencing with relevant primers (Table 2) (18).
Large-scale protein expression and puriﬁcation. A fresh overnight culture of BL21*(DE3)/pET-His6-
ESAT-6-Pet-BP was diluted 1/100 in 2 liters of LB medium with carbenicillin and grown at 37°C with
aeration to an OD600 of 0.5, followed by induction of protein expression with 0.5 mM IPTG. After 2 h,
the cells were removed by centrifugation (6,000  g, 30 min, 4°C), and the supernatant was ﬁltered
through a 0.22-m ﬁlter and supplemented with a protease inhibitor cocktail (Roche). The supernatant
was applied to a buffer-equilibrated 1-ml HisTrap column (GE Healthcare) at a low rate at 4°C by use of
a peristaltic pump. The column was connected to an Akta puriﬁer, and the standard protocol for
His-tagged protein puriﬁcation under native conditions was followed. The equilibration/wash buffer
contained 50 mM sodium phosphate, 500 mM NaCl, and 10 mM imidazole (pH 8.0), while the elution
buffer contained 50 mM sodium phosphate, 500 mM NaCl, and 500 mM imidazole (pH 8.0). The eluted
His-tagged protein was buffer exchanged into 10 mM Tris, 30 mM NaCl, pH 8.0, concentrated through
a 30-kDa Vivaspin centrifugation device (Sartorius), and quantiﬁed using a Bradford protein assay kit
(Bio-Rad). The protein sample was aliquoted and stored at 20°C until further use.
Mouse immunization studies. Wild-type C57BL/6 mice were purchased from HO Harlan Olac Ltd.
(Bicester, United Kingdom). The mice were maintained under standard animal housing conditions in
accordance with local and UK Home Ofﬁce regulations. Overnight cultures of Salmonella strains for immu-
nization studies were inoculated into fresh LBmedium (with carbenicillin where appropriate) at a 1/20 dilution
and grown at 37°C to an OD600 of 1. The cells from 1 ml of culture were harvested by centrifugation and
washed twice with PBS. The cells were resuspended in 1 ml PBS. Naive female C57BL/6 mice (6 to 8 weeks
old) were injected intraperitoneally (i.p.) with 5 105 CFU. The exact injected dose was conﬁrmed by plating
dilutions of the cell suspension used for immunization on LB agar plates without antibiotic. The mouse
cohorts included 3 to 8 animals per construct. An untransformed Salmonella strain was used as a negative
control. For in vivo restimulation of memory cells, mice were injected intravenously (i.v.) with 100 g
T-dependent ESAT-6 peptide (M. tuberculosis ESAT-6 4-17 [QQWNFAGIEAAASA]; Proimmune) in 100 l PBS 4
h prior to sacriﬁce. The mice were sacriﬁced at 7 or 42 days postimmunization, and spleens, livers, and blood
were retained for analysis. For longer experiments, blood samples were also taken from a superﬁcial tail vein
at 7, 21, and 35 days postimmunization. The blood samples were allowed to clot at 37°C for 1 h, and the serum
was separated by centrifugation at 15,000 g for 20min. The serumwas aliquoted and stored at80°C. Each
immunization experiment was repeated at least twice.
Determining bacterial burdens in mouse organs. Weighed liver sections and whole spleens were
passed through a 70-m nylon cell strainer (BD Falcon) with 1 to 3 ml of PBS. The collected cell suspensions
were diluted in PBS and plated onto LB agar plates without selection. The recovered colonies were scored,
and the bacterial burden per whole organ was calculated. One hundred randomly selected colonies (or all if
fewer were recovered) from each mouse’s spleen and liver were patch plated onto a pair of LB agar plates,
one supplemented with carbenicillin, to determine plasmid retention. A few antibiotic-resistant colonies (one
per mouse) were picked at random and tested for antigen secretion as described above.
Analysis of T cell responses. ESAT-6-speciﬁc T cell responses were analyzed 7 and 42 days after
immunization. To isolate splenocytes, spleens were passed through a 70-m nylon cell strainer and
washed three times with RPMI medium. The cells were harvested by centrifugation at 300  g for 6 min
at 4°C, resuspended in 1 ml of red blood cell lysis buffer (Sigma), and incubated at room temperature for
5 min. RPMI medium (Gibco) was then added directly to the lysed solution, ensuring that the clumps
were resuspended. The cells were harvested as described above, resuspended in 5 ml ice-cold staining
buffer (SB; Dulbecco’s PBS [DPBS], 2.5 mM EDTA, 10% fetal calf serum [FCS]), and passed through an
additional 70-m strainer. One third of the cell mixture was pelleted as described above and resus-
pended in 100 l of SB containing a phycoerythrin (PE)-conjugated ESAT-6 tetramer at a 1/100 dilution
[class II MHC I-A(b) M. tuberculosis ESAT-6; NIH Tetramer Core Facility] and brefeldin A (10 g/ml). The
reaction mixtures were incubated for 1 h in a room temperature water bath. The cells were washed twice
with SB, pelleted as described above, and resuspended in 400 l SB. Two hundred microliters of
tetramer-stained cells was used for standard T/B cell receptor staining with a cocktail of mouse-speciﬁc
ﬂuorescent antibodies (BD Biosciences), while 50-l aliquots of unstained splenocytes were used for
single staining reactions. The reaction mixtures were incubated on ice in the dark for 0.5 to 1 h, washed
twice with SB, and ﬁxed and permeabilized with Cytoﬁx/Cytoperm Plus (BD Biosciences) overnight at 4°C.
The cells were washed as described above and stained for intracellular interleukin-2 (IL-2) (Alexa Fluor
488) and IFN- (PE-Cy7) (BD Biosciences) or IFN- only for 1 h on ice. Washed cells were supplemented
with 10 l of Spherotech blank particles for cell enumeration. Samples were run on a BD LSR Fortessa
X-20 ﬂow cytometer and analyzed using FlowJo software.
ELISA. A standard indirect enzyme-linked immunosorbent assay (ELISA) protocol was used for
detection of the antigen-speciﬁc IgG in the immunized mouse sera. Brieﬂy, Nunc MaxiSorp 96-well plates
were coated with 5 g/ml of puriﬁed His6-ESAT-6-Pet-BP protein or S. Typhimurium LPS (Sigma) in 0.1
M carbonate buffer, pH 9.6 (overnight, 4°C). The plates were washed three times in wash buffer (PBS,
0.05% Tween 20), incubated with PBS-1% bovine serum albumin (BSA) for 1 h at 37°C, and washed as
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described above. The plates were incubated for 1 h at 37°C with 3-fold serial dilutions of mouse sera in
dilution buffer (PBS, 0.05% Tween 20, 1% BSA), followed by three washes with wash buffer. The plates
were incubated with a relevant AP-conjugated secondary antibody in dilution buffer for 1 h at 37°C (goat
anti-mouse IgG–AP [1/10,000 dilution; Sigma] for protein- and LPS-speciﬁc total IgG or goat anti-mouse
IgG1–AP, goat anti-mouse IgG2a–AP, or goat anti-mouse IgG2b–AP [1/2,000; Southern Biotech] for
protein-speciﬁc IgG isotypes). The plates were washed as described above and developed using
SigmaFAST p-nitrophenyl phosphate substrate (Sigma); 405-nm readings were taken at regular intervals
by use of a Labsystems Multiscan MS plate reader. The IgG titers were estimated using the speciﬁed
threshold OD method.
Statistical analysis. All statistical analyses were done using Prism software. The nonparametric Mann-
Whitney test was used for pairwise comparisons (with statistical signiﬁcance set at P values of 0.05).
Study approval. All animal procedures were carried out in strict accordance with local ethical
approval from the University of Birmingham and the UK Home Ofﬁce (project license 30/2850) as covered
by the Animals (Scientiﬁc Procedures) Act 1986.
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